Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says
The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.
Novel Plasma Assays That Selectively Detect Tau Characteristics Will Refine Clinical Study of Alzheimer Disease
The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.
FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose
Your daily dose of the clinical news you may have missed.
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.
GLP-1 Medications Need a Permanent Place in Primary Care, Says Obesity Medicine Specialist
Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.
Use of Weight-Loss Drugs Increased Among US Adolescents After AAP Guideline Release
New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.
Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial
The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.
Reframing Vaccines as Innovation: A Strategy to Rebuild Patient Trust in Primary Care
Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.
Study Sheds Light on Public Perception of Physicians Who Use AI: Daily Dose
Why Should Primary Care Clinicians Shift to AI-Powered Cognitive Assessment? Experts Explain
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.
11 US Vaccine Policy Updates: How Will They Affect Your Practice?
Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.
Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD
The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.
Nearly 17 Million US Youth Found Eligible for GLP-1 RA Therapy and Most Because of Obesity
An NHANES-based cross sectional study found that 1 in 5 of the treatment-eligible youth lacked adequate insurance and one-third had no routine place for health care.
Primary Care Needs the Right Tools to Identify MCI Early, Says Rodney Swenson, PhD
If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.
The Biggest Threat to Vaccine Confidence in the US: An Expert Discussion
Amesh Adalja, MD, urges physicians to use their trusted position to counter widespread vaccine misinformation and strengthen patient confidence in immunization.
Digital Asthma Program Improves Symptom Control in Adults: Daily Dose
Cognition is The Next Vital Sign: An Interview with David J Libon, PhD
A cognitive health assessment will soon be as routine as taking blood pressure or pulse ox, says neurocognitive researcher David J Libon, PhD. He talks more about that future.
When Guidelines Diverge: Navigating Vaccine Recommendations in 2025
Amesh Adalja, MD, advises physicians turn to specialty societies for evidence-based, reliable recommendations this respiratory virus season.
Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain
The NaV1.8 ion channel inhibitor was planned as a follow-up to the company's first nonopioid for acute pain, suzetrigine, approved by the FDA in January 2025.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Reframing Vaccines as Innovation: A Strategy to Rebuild Patient Trust in Primary Care")
